Terrapin, Sanwa Kagaku Kenkyusho Co. Ltd. deal

Terrapin and Sanwa will use Terrapin's TRAP molecular fingerprinting technology to develop compounds to treat diabetes mellitus and insulin resistance. The companies will focus on orally active substances that lower blood glucose through their action on the insulin signal transduction pathway. Terrapin could receive up to $22.5 million in license fees, R&D funding, milestones and equity investments, and is eligible for royalties. Sanwa receives commercialization rights in Japan and Asia, while Terrapin retains rights in other markets. ...